REVEFENACIN
| Brand name | YUPELRI |
|---|---|
| Active ingredient | REVEFENACIN |
| Strength | 175MCG/3ML |
| Dosage form | SOLUTION |
| Route | INHALATION |
| Modality | Small molecule |
| FDA approval | November 2018 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11484531 | October 2039 | use U-2440 |
| 12285417 | August 2039 | use U-2440 |
| 12048692 | August 2039 | use U-2440 |
| 8541451 | August 2031 | substance |
| 11691948 | July 2030 | product |
| 10550081 | July 2030 | substance |
| 11008289 | July 2030 | use U-2440 |
| 11858898 | July 2030 | substance, product |
| 9765028 | July 2030 | substance |
| 7288657 | October 2028 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.